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The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults 
with overactive bladder syndrome: A systematic review 
Abstract 
Aims: To evaluate effectiveness of transcutaneous tibial nerve stimulation (TTNS) 
for treating adults with overactive bladder (OAB) of idiopathic or neurogenic origin, 
using a systematic review of the literature.  
Methods: Systematic searches of four databases were undertaken between 1980 
and 2017. Included studies investigated effects of TTNS on OAB. Study selection, 
data extraction, quality appraisal was performed by two independent reviewers. 
Narrative analysis was undertaken where meta-analysis was not possible due to 
study heterogeneity. Meta-analysis of RCTs was performed using a fixed effects 
model.  
Results: 10 RCTs and 3 prospective cohort studies involving 629 participants were 
reviewed. Meta-analysis of two trials comparing TTNS with sham showed mean 
reduction in total ICIQ Urinary Incontinence Short Form (ICIQ-UI SF) associated with 
TTNS of -3.79 (95% CI -5.82, -1.76; P=0.0003, I2=25%). Narrative review showed 
TTNS and antimuscarinic treatment were equally effective (four trials), TTNS 
provided greater benefit for OAB symptoms than behavioural interventions (two 
trials), tibial nerve and sacral foramen stimulation were equally effective but 
combined stimulation was most effective (one trial). Significant improvements in OAB 
symptoms were reported by 48-93% participants and UI cure rates of 25-45%. No 
adverse events were reported. 
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Conclusions: Limited evidence is provided that TTNS is an effective, safe 
intervention for idiopathic OAB in adults and may be of benefit in those with 
neurogenic OAB. Further studies are essential to confirm these results as well as to 
determine efficacy and associated costs for specific patient groups, most effective 
stimulation dosage, duration of effect and stimulation regimes for longer-term 
maintenance. 
Keywords: Transcutaneous electric nerve stimulation; tibial nerve; neuromodulation; 
urinary bladder, overactive. 
Introduction  
Overactive bladder (OAB) is an increasingly prevalent condition affecting 12-17% of 
the adult population1,2  increasing to 30-40% in those aged 75 and over 3. By 2018, it 
is estimated that as many as 20% of the population worldwide will suffer from OAB4. 
Although not life-limiting OAB is nevertheless life-altering and may have profound 
impact on a person’s quality of life, ability to participate and overall wellbeing 5,6,7.  
Urgency was the most commonly experienced bothersome lower urinary tract 
symptom (LUTS) in a large cross-sectional survey of  3727 individuals8 and 
symptomatic urgency urinary incontinence (UUI) was reported as the most 
bothersome symptom at an individual level8. 
An algorithmic approach is taken to managing OAB, based on implementation of 
evidence-based recommendations arising from current research evidence. Lifestyle 
changes and behavioural interventions are first-line therapy in all guidance 9, 10, 11 
followed by various forms of second-line pharmacotherapy,  before escalating to 
more invasive forms of treatment such as Botox, or sacral nerve stimulation where 
these therapies are found to be ineffective.  While lifestyle and behavioural 
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intervention is fundamental to managing all forms of bladder dysfunction, a 
significant proportion of those who go on to drug-based treatments will experience 
adverse effects to such a degree that they discontinue use and longer term 
adherence to antimuscarinic drugs is poor 12, 13.  Hence alternative, non-
pharmacological approaches to long-term management of OAB are increasingly 
sought. The ongoing nature of OAB means that total permanent resolution is unlikely 
and relapsing-remitting patterns across the course of the condition have been 
described 14,15,16 . Such natural history and progression patterns suggest that OAB is 
best viewed as a ‘long-term condition’ which requires to be self-managed by the 
person, with appropriate support to do this effectively.  
There is grade A evidence that electrical stimulation of the tibial nerve by inserting a 
34 gauge needle (percutaneous tibial nerve stimulation (PTNS) is an effective and 
safe treatment for idiopathic OAB17, 18 and the suggestion that this may also be the 
case for neurogenic lower urinary tract dysfunction is under investigation19. PTNS 
was first introduced in 199920 and has been routinely available for a number of years, 
receiving FDA approval in 2000 for office based treatment of OAB and approval from 
NICE in 20069. Despite only limited understanding of its mechanisms of action it 
occupies an important position in the OAB treatment algorithm between low-
technology lifestyle, behavioural and pharmacological interventions and intensive, 
invasive surgical or implanted treatments such as Botox or sacral nerve stimulation. 
However PTNS involves delivery of an extended programme of treatment (usually 12 
sessions of 20-30 minutes duration) by trained staff in a secondary care or clinic 
environment and thus completion involves a significant time and travel commitment 
by the person with OAB. Additionally, although acknowledged as effective, the costs 
of the treatment programme delivery and ongoing maintenance therapy may prohibit 
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availability and routine use in some healthcare services and countries. Given these 
limitations a growing number of studies have investigated the transcutaneous route 
for delivering tibial nerve stimulation. This alternative non-invasive treatment is safe, 
using only surface electrodes and may be self-administered by the person in their 
own home, thus supporting self-management and avoiding travel and staff costs21. It 
is convenient because the programme of delivery is decided entirely by the person 
with OAB and can therefore reflect personal choices and lifestyle.  
Systematic reviews of effectiveness of PTNS alone 18, 22,23,24 and general tibial nerve 
stimulation (including PTNS and TTNS), for OAB and urinary dysfunction25 and for 
neurogenic lower urinary tract dysfunction19  have been published. However there is 
no systematic review of the evidence in relation to TTNS alone. The systematic 
review reported here aimed to establish evidence of effectiveness of TTNS in the 
treatment of OAB in adult men and women.  
Methods 
The systematic review was carried out according to the review protocol published in 
PROSPERO (CRD42016041250) using Cochrane Collaboration methods and 
reported in accordance with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) framework26. 
Literature search strategy 
Systematic searches for published papers indexed in MEDLINE, EMBASE, CINAHL, 
and the Cochrane Database of Systematic Reviews between 1980 and January 
2017 were undertaken using a strategy combining selected subject headings and 
keywords relating to TTNS, OAB, UUI, mixed UI (MUI) and study design to 
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determine effectiveness of the intervention. The search strategy was developed for 
use in Medline (Appendix 1) and amended for use in other databases. Manual 
searching of reference lists, relevant systematic reviews and guidelines, was also 
performed. Results were filtered for English language. 
Selection criteria 
Included study designs were randomised controlled trials (RCT) and prospective 
observational cohort studies and inclusion was determined by the PICO criteria:  
Study Participants required to be adults aged < 18 years with reported subjective 
complaints of idiopathic or neurogenic OAB or MUI. Overactive bladder was defined 
according to the ICS definition as ‘urinary urgency, usually accompanied by 
frequency and nocturia, with or without urgency urinary incontinence, in the absence 
of urinary tract infection or other obvious pathology’ and mixed UI as ‘the complaint 
of involuntary loss of urine associated with urgency and also with effort or physical 
exertion, or on sneezing or coughing’27. The intervention was TTNS, used to treat 
OAB or MUI. Comparators were a placebo control, another intervention, a different 
site of transcutaneous electrical stimulation, PTNS or TTNS as an additional 
intervention. Primary outcomes were self-reported symptoms of urgency, frequency, 
nocturia, amount of leakage or number of episodes of UI. Secondary outcomes 
included health-related quality of life assessed using standardised measures, 
adverse events reports and urodynamic changes.   
Study selection 
Eligible studies were selected in a two stage process. Using the broad criteria of 
OAB or MUI and TTNS, two reviewers (from JB, LC, SD, FD) independently 
screened all titles and abstracts, where available, of bibliographic records retrieved. 
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Full-text copies of potentially relevant studies were retrieved. Two reviewers then 
used the pre-determined PICO selection criteria to assess eligibility. Disagreement 
was resolved by discussion with a third reviewer. 
Data extraction and Quality Appraisal 
Two reviewers (from JB, LC, SD, FD) extracted data independently using a review-
specific tool. Data extracted included details of study design and methods; study 
participants including sex and age; urinary symptoms, dysfunction and method of 
measurement; TTNS protocols, outcomes, conclusions and adverse effects. 
Extracted data were cross-checked and disagreements resolved by consensus. 
Where indicated, authors were contacted and asked to provide missing information.  
Independent assessment of methodological quality was conducted for trial designs 
(RCTs and CCTs) using the Cochrane Risk of Bias tool28. Quality was assessed as 
being of low/unclear/high risk of bias against seven criteria: random sequence 
generation (selection bias), allocation concealment (selection bias), blinding of 
assessors (performance bias), blinding of outcome assessment (detection bias), 
incomplete outcome data (attrition bias), selective reporting (reporting bias),and 
‘other’. Prospective observational cohort studies were assessed using the NICE 
quality assessment tool 29 to address external validity of the studies in terms of the 
sample representativeness within the wider population, consecutive selection of 
participants, clarity of aims and outcomes targeted description of findings and 
sample and stratification of outcomes. The maximum total score was 8. 
Data analysis/synthesis 
Analysis was undertaken in RevMan 5.2 30. For studies which reported mean 
differences a meta-analysis was performed to pool estimates of effect. Forest plots 
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were produced to visually assess the association across the included studies and the 
corresponding 95 % confidence intervals (CI). The chi-squared test was employed to 
determine strength of evidence that heterogeneity was genuine, where P < .10, 
rather than P<.05 was considered indicative of statistically significant heterogeneity, 
due to the small number of studies and sample sizes 31. The I2 statistic was used to 
quantify inconsistency, the percentage variability in effect estimates due to 
heterogeneity between studies rather than sampling error within studies. An I2 value 
over 50% may indicate substantial heterogeneity. Pooled results were estimated 
using a fixed effects inverse-variance meta-analysis for difference in means between 
intervention and control groups with 95% CI.  A fixed effect model is the best one to 
use when all included studies are functionally identical, there are no studies with 
extreme effect sizes that could influence the results and the number of studies is 
very small, meaning it may be difficult to estimate the between-study variance with 
any precision. Possibility of publication bias was evaluated by visual inspection for 




Database searches identified 1960 unique bibliographic references. Review of titles 
and abstracts resulted in the exclusion of 1938 papers that did not meet the broad 
inclusion criteria of reporting on TTNS and urge or mixed UI. Full texts were retrieved 
for the remaining 22 papers. These papers were screened for eligibility using the 
detailed PICO criteria. This resulted in the exclusion of a further 9 papers leaving 13 
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papers in the review (Fig. 1). Papers were rejected because they did not report on 
TTNS (n=8) and the full text of one paper could not be sourced. 
 
Insert figure 1 here: Flow chart of study selection 
 
The 13 papers reported 10 RCTs32-41and 3 prospective cohort studies42,43,44. 
Included studies were published between 2002 and January 2017 with 9 of the 10 
trials and 2 of the 3 prospective observational studies published since 2009. 
Extracted data from the 13 papers are presented in the table of characteristics 
(Table 1) 
Insert table 1 here: Study characteristics 
 
Methodological quality of included studies 
The summary of the overall risk of bias across the 10 RCTs is provided in figure 2. 
Risk of bias was assessed to be unclear for the majority of the trials as a 
consequence of inadequate reporting which was a common feature.  Main sources 
of bias were assessed as lack of random sequence generation, poor allocation and 
outcomes assessment blinding and selective outcome reporting particularly in 
relation to attrition.  The prospective observational studies were all assessed as high 
quality with scores of 6, 7 and 7 from a maximum of 8 using the NICE Quality 
Assessment Tool29. Two were single site studies42, 43, one did not recruit 
consecutive patients44 and one did not report stratified outcomes42.  
 




Characteristics of studies 
Overall the 13 included studies enrolled a total of 629 participants: 437 females 
(70%) and 176 males (28%), with 16 (2%) participants sex not reported. The 3 
prospective cohort studies included a total of 157 recipients of TTNS, 41 males 
(26%) and 116 females (74%). The 10 RCTs enrolled a total of 472 participants, [321 
women (68 %) and 135 men (32%)], of which 254 (54%) received the TTNS 
treatment. Thirty six participants in control groups received inactive sham (18%)32, 33, 
37,142 (56%) received anticholinergic drugs [solifenacin succinate  (49, 19%)34,  
oxybutynin immediate release (10, 4%)39 and extended release (84, 33%)]35, 39 
bladder training and pelvic floor muscles training (26, 10%)38, stretching exercises 
(12, 5%)36, sacral foramina transcutaneous electrical stimulation40 or no treatment (9, 
4%)41.  Five RCTs were conducted only on women32,35,38,39,41, one on men only436 
and 4 included mixed sex samples33,34,37,40.  The 3 prospective cohort studies 
included both men and women. Participant ages encompassed the adult ages from 
18 to 94, although in 10 of the 13 studies the mean age was between 45 and 69 and 
only one study33 included adults over the age of 80 (table 1). Idiopathic OAB was the 
focus of 7 of 10 RCTs including the five women-only trials, the trial in older care 
home residents33 and the trial comparing different stimulation sites40. Other studies 
focused on neurogenic OAB arising from MS43,44, Parkinson’s37, stroke36 and spinal 
cord injury34.   
Intervention: The TTNS intervention was not standardised across the studies and a 
range of dosages were delivered. The duration of treatment programme ranged from 
4 to 12 weeks (mean 7.2 weeks, SD 3.6) and the total number of included sessions 
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from 5 to 90 (mean 21.6, SD 23). The length of individual stimulation sessions was 
30 minutes in all but 3 studies40,43,44 where it was 20 minutes. Timing of session 
delivery varied from daily stimulation in 3 studies40,43,44, twice weekly in 7 
studies32,33,34,35,36,37,39 and once weekly in 2 studies38,41. 
Comparators: Three of the 10 RCTs compared TTNS with a sham32,33,37,  4 trials 
compared TTNS with an anticholinergic drug34,35,39,41, 1 trial compared TTNS with 
exercise36, 1 trial compared TTNS as an adjunct to first-line behavioural therapy with 
behavioural therapy alone38 and 1 trial compared two stimulation sites40. The three-
arm trial reported by Souto et al39compared TTNS with a group receiving extended 
release oxybutynin alone and a group receiving TTNS in addition to the drug. 
Surbala et al40 compared stimulation of the transcutaneous tibial nerve and sacral 
foramina sites and a combination of the two. Schreiner et al38 compared two groups 
of women who underwent a first line behavioural intervention involving 12 weeks of 
bladder training and pelvic floor muscle training, with half also receiving 12 weeks of 
TTNS. 
Treatment outcomes 
All but one study40 assessed clinical symptoms parameters using a voiding diary to 
measure primary or secondary outcomes. A range of standardised and validated 
patient reported symptom tools were also used including: The Overactive bladder 
questionnaire45 (OABq)32,35; International Prostate Symptom Score46 (IPSS)33,41;  
International Consultation on Incontinence Questionnaire – Urinary Incontinence 
Short Form47 (ICIQ-UI SF)33,37,38;  Overactive Bladder Questionnaire48 (OAB V8)37;  
Overactive Bladder Syndrome Score49 (OABSS)40;  Urinary Symptom Profile50 
(USP)43.  Quality of life measures were equally varied and included Incontinence 
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Quality of Life51 (I-QoL)34,41;  Mesure du Handicap Urinaire52(MHU)43,44; Short-form 
Urinary Distress Inventory53(UDI-6)40;  Short-form Incontinence Impact 
Questionnaire53(IIQ-7)40;  Qualiveen54 (QV)44. Follow up was limited in the majority of 
studies. Eight of the 10 RCTs measured outcomes solely at the end of the treatment 
period, which ranged from 4 weeks32,34,40  to 12 weeks35,38,39. Two of the prospective 
cohort studies measured outcomes at two points: at 4 weeks43,44, 12 weeks44 and 
10.8 months43. Treatment outcomes are shown in table 2.  Given the heterogeneity 
in outcome measures used, data pooling for meta-analysis was not possible for the 
majority of outcomes. 
Insert table 2 here – Review study outcomes 
Bladder diary changes  
When compared to sham, TTNS resulted in a significant reduction in urgency and 
nocturia in women with idiopathic OAB32 and adults with Parkinson’s 37. 
Improvements in UUI were observed but not significant (Table 2). When directly 
compared to antimuscarinic drug treatment TTNS and extended release oxybutynin 
produced similar significant improvements in frequency, urgency and UUI and 
reduction in pad use in women with idiopathic OAB35 (Table 2). In adults with 
neurogenic OAB secondary to spinal cord injury the volume per catheterisation and 
volume of daily leakage were reduced equally in those taking solifenacin succinate 
and those receiving TTNS34. In a comparison between lower limb stretching 
exercises and TTNS in men with post-stroke OAB, at six weeks and 12 months the 
TTNS group reported significantly improved urgency, frequency, nocturia and UUI36. 
There were no such changes found in the exercise control group; however the only 
statistically significant between-group differences were reported frequency at both 
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time-points and nocturia at 12 months36. Adding TTNS to standard first line 
behavioural interventions of bladder training and pelvic floor muscle training was 
effective for frequency, nocturia and urgency UI in older women with idiopathic 
OAB38. Significant improvements were shown between the TTNS-enhanced group 
after 12 weeks, compared to the behavioural treatment group in frequency, nocturia 
and episodes of urgency UI.  In one RCT undertaken with older residents of care 
homes a significantly greater reduction in post void residual urine volume of 55ml 
was found in the TTNS group compared to the sham33. In summary, authors 
conclusions for voiding diary outcomes are that TTNS is effective for women with 
OAB32,38, neurogenic bladder dysfunction in Parkinson’s37 and following stroke36 and 
as effective as some anticholinergic drug treatment in women35 and those with spinal 
cord injury34.  
OAB symptoms scores  
In terms of patient-reported outcomes using standardised measures, when 
compared to sham intervention the IPSS scores of frail older adults treated with 
TTNS were significantly improved, reducing by a median of 7 points over the six-
week intervention period33. In a group of Parkinson’s patients the OAB V8 scores in 
those receiving TTNS improved significantly compared to the sham group where 
there was little change observed37(Table 2). Comparisons between the effects of 
TTNS and different drugs on OAB symptoms showed that multimodal intervention 
(TTNS plus extended release oxybutynin) was more effective than TTNS alone over 
12 and 24 weeks, however effects of TTNS were sustained over 24 weeks whereas 
the effects of the single drug therapy were lost39.  The results of one small clinical 
controlled trial41 suggested that TTNS was as effective as immediate-release 
oxybutynin but more acceptable to women with OAB. When two different stimulation 
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sites were compared equal effectiveness was found for reducing OAB symptoms 
with sacral foramina and tibial nerve sites, however a greater effect on the OABSS 
was produced by stimulation of both sites simultaneously40. Thus in summary, 
authors of all studies indicate TTNS to be effective for reducing reported bladder 
symptoms, whether compared to sham33,37, compared to antimuscarinic drugs39,41, 
with other stimulation sites40 or over time43,44. 
Quality of Life outcomes indicated TTNS to be associated with significantly greater 
improvement than sham intervention on the OABq32. In three trials comparing TTNS 
and drug therapy35,39,41 in women with idiopathic OAB, quality of life improved 
equally in all (Table 2). There were similar improvements in all 3 domains of the 
OABq with TTNS and ERO35, however the TTNS was associated with more 
prolonged reductions in symptom bother than the ERO in one study 39, although 
combining the two resulted in the most improved quality of life. Similarly combined 
stimulation of sacral foramina and tibial nerve resulted in greater UDI-6 and IIQ-7 
improvements than either site alone, but all were associated with significantly 
improved quality of life40.  
Effectiveness of TPTNS: 
Variability in outcome measures and reporting (despite contacting several authors), 
resulted in limited opportunity to pool data in meta-analyses. However sufficient data 
were extracted from two studies33,38 to enable meta-analysis of mean changes in the 
ICIQ-UI SF scores following a 12 session programme of TTNs. As shown in the 
forest plot (figure 3), compared to those in the control group meta-analysis 
demonstrated a clinically55 and statistically significant mean reduction of 3.88 points 
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on the total ICIQ-UI SF (-5.59, -2.16; P<0.00001; I2= 25%; 40 participants) in those 
who received TTNS.    
Insert figure 3 here: Forest plot 
 
Observational studies outcomes 
The three prospective cohort studies reported changes in bladder function 
associated with use of TTNS. Ammi (2014)43, in adults with refractory OAB and 
DeSeze(2011)44 in adults with MS and refractory OAB showed daily TTNS sessions 
resulted in significant clinical improvements in 53% and 83% participants  
respectively at 30 days (table 2), which continued to 90 days in one study44. 
Improvements in standardised patient-reported measures of Mesure du Handicap 
Urinaire (MHU) and Urinary Symptom Profile (USP) were reported43, together with 
significant improvements in urgency, frequency, number of weekly leaks and 
percentage of continent patients, at both 30 days and 90 days44. Volume at first 
involuntary detrusor contraction and maximum cystometric capacity were 
significantly increased in 50% of participants with OAB of neurogenic (n=37) or 
idiopathic (n=7) origin, receiving a single session of TTNS42. 
Combined outcome overall  
As shown in table 2, results from 9 studies report significant improvement in LUTS in 
48% to 93% of participants undergoing TTNS intervention32,33,35,36,38,39,41,43,44. Cure 
rates of 25% to 45% for UI were reported in three studies35,36,44.  




Our systematic review of 10 RCTS and 3 prospective cohort studies involving 629 
participants indicates that 48-93% participants achieved significant symptom 
improvement following a programme of TTNS. Meta-analysis of data from two 
studies found a clinically and statistically significant reduction of 3.88 points on the 
ICIQ-UI SF, indicating that TTNS is an effective, non-invasive treatment for OAB in 
older adults. Additionally the absence of any reports of stimulation-related adverse 
events in the review confirmed the safety and tolerability of TTNS across adult 
populations for both idiopathic and neurogenic OAB. 
Despite these promising findings there are a number of factors which suggest the 
need for caution in interpreting the review results. The studies were generally small, 
only two of the RCTs recruited according to a power calculation35,39 and risk of bias 
in the RCTs was unclear or high for the majority. Heterogeneity was marked in 
relation to participants’ age, sex, medical and urological conditions with a mix of 
idiopathic and neurogenic bladder dysfunction of variable duration and  a tendency 
for more moderate than severe OAB symptoms represented.  
The TTNS intervention was not standardised and the dose delivered varied between 
studies, although all used low frequency stimulation of 10-20 Hz. In terms of hours of 
stimulation this ranged between 2.5 hours and 12 hours in the RCTs and 10 and 30 
hours in the prospective observational studies, showing the wide variation. Currently 
there is no evidence of superior efficacy with longer duration of stimulation and the 
optimum intervention programme or duration has not yet been established. A study 
using percutaneous tibial nerve stimulation suggests more frequent stimulation leads 
to a more rapid response however there was no difference between weekly and 
three times weekly dosages with regard to overall treatment outcome57. Primary and 
secondary outcomes measured were varied and included individual LUTS, different 
16 
 
types of UI, changes in quality of life and urodynamic parameters. Eleven validated 
tools were used to measure outcomes across 13 studies. Due to differences in 
reporting of data, where some studies reported mean results and others mean 
changes and the lack of response from authors contacted to provide further 
information, data pooling was not possible for most reported outcomes. There was a 
lack of long-term follow up beyond 12 weeks; one trial reported outcomes at 6 
months39 and one at 12 months36 and one prospective observational study followed 
women for a mean of 10.8 months43. Thus duration of potential effect is unclear and 
should be investigated in future research. 
Economic evaluation was not formally addressed in any of the included studies; 
however Manriques (2016)35 discussed the affordability of TTNS stating a one-off 
cost of 45 euros for the TTNS equipment compared to a monthly average cost of 
antimuscarinics of 50 euros. Recent audit has shown costs associated with TTNS to 
be considerably lower than three routinely used anticholinergics in the UK at 2015 
costs58. Nevertheless there is a lack of information on long-term economic aspects 
and comparison with other therapies, such as percutaneous TNS. Such information 
is required before implications for future practice can be reliably considered.  
An important clinical issue is the place of TTNS in the OAB treatment algorithm. This 
review indicates the potential effectiveness of TTNS for use in idiopathic OAB and its 
safety for treating neurogenic OAB. These findings, together with the utility of TTNS 
in a supported self-management regimen22,25 and the low cost of the intervention58 
make TTNS an attractive option for inclusion earlier in the treatment algorithm. 
Schreiner (2010)38 recommended that it is included as first line conservative therapy 
as an adjunct to lifestyle and behavioural conservative management in older women 
with UUI. Given its safety and the passive nature of the intervention there is also 
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potential for application in clinical situations where behavioural, lifestyle and 
pharmacological therapies might be inappropriate or contra-indicated, such as in the 
older, cognitively impaired population.  
Previous systematic reviews have combined percutaneous (needle-electrode) TNS 
and transcutaneous (surface electrode) TNS in the same review19,23,56, hence the 
current lack of clarity in our understanding of effectiveness, cost-effectiveness and 
best position in the treatment algorithm for each intervention and the tendency to 
consider them as equivalent.  This situation fails to recognise the potential to target 
each more carefully. While the possibility of equal effectiveness for the two routes of 
administration is accepted, it is also conceivable that there are differing mechanisms 
of action associated with each, which have yet to be identified. Our review results for 
TTNS suggest similar success rates to those achieved in the PTNS studies. Given 
the current lack of reliable information, all reviews of TNS regardless of type,  
highlight the need for greater information, particularly in terms of identifying 
predictors of those who will respond to treatment and likely success rates. 
Conclusion 
All studies in this systematic review demonstrate some benefit from TTNS, in terms 
of patient reported and urodynamic parameters. Safety and tolerability of the 
intervention is confirmed. However, in view of the limited quality of evidence  further 
research is necessary to confirm effectiveness for specific patient sub-groups, as 
well the magnitude of effect sizes associated with use of TTNS for treating OAB in 
adults, the optimal stimulation programme, potential sustainability and duration of 
effect. The place of the transcutaneous route of delivery in the treatment algorithm, 
in contrast to the more costly and labour-demanding percutaneous route has yet to 
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be clarified, particularly in relation to the promising role for TTNS in ongoing self-
management of OAB. Nevertheless, given its safety, low cost, ease of application 
and potential to support self-administration, there is a clear impetus for further 
research to establish definitive evidence on the role of TTNS as second-line therapy, 
after lifestyle and behavioural changes have been implemented and as a direct 
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Table 2 – Review study outcomes 
Key: I = Intervention; C = Comparison; TTNS = Transcutaneous Tibial Nerve Stimulation; OAB = overactive bladder; BD = bladder diary; UUI = urge urinary incontinence; 
AUASI = American urological Association Symptom Index; ICIQUI-SF = International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form; LUTS 
= Lower Urinary Tract Symptoms; OABV8 = Overactive Bladder Awareness Tool; NDO=Neurogenic Detrusor Overactivity; ERO = Extended Release Oxybutynin; IPSS = 
International Prostate Symptom Score; SF = Sacral Foramina Stimulation; OABSS = Overactive Bladder Symptom Score, GRA = Global Response Assessment; OABq = 
Overactive Bladder Questionnaire, SF-36= 36-Item Short Form Health Survey; PVR = post-void residual urine volume; SS = solifenacin succinate; VPC = Volume Per 
Catheterisation; BT = Bladder Training; PFME = Pelvic Floor Muscle Exercises; ERO = Extended Release Oxybutynin; UDS = urodynamic studies; DI = Detrusor 
Instability; USP=Urinary Symptom Profile; MHU = Mesure du Handicap Urinaire; NOUR = non-obstructive urinary retention; GRA = Global Response Assessment; FIDC = 
First Involuntary Detrusor Contraction; MCC= Maximum Cystometric Capacity; OR = odds ratio; CI = confidence interval; NS = Not significant. 
 
